CompletedNCT00003863
Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Raju Chaganti, PhDMemorial Sloan Kettering Cancer Center
- Intervention
- comparative genomic hybridization(genetic)
- Enrollment
- 391 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2005
Study locations (30)
- Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- Naval Medical Center - San Diego, San Diego, California, United States
- Veterans Affairs Medical Center - San Diego, San Diego, California, United States
- UCSF Comprehensive Cancer Center, San Francisco, California, United States
- Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- Lombardi Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- Veterans Affairs Medical Center - Washington, DC, Washington D.C., District of Columbia, United States
- Broward General Medical Center, Fort Lauderdale, Florida, United States
- Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
- CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States
- Veterans Affairs Medical Center - Chicago Westside Hospital, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003863 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha